GenoMed, Inc. selects leading health care technology firm as its Outcomes Measurement Partner for its unique physician-direct program.
ST. LOUIS--(June 13, 2002) - GenoMed, Inc- ("the Company" or "GenoMed") (National Quotation Bureau’s Pink Sheets Symbol GMED), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has picked a partner to design, measure and report on clinical pathways and health outcomes for GenoMed’s innovative health improvement programs. Strategic Healthcare Programs, LLC, of Santa Barbara, California, was GenoMed’s choice for this endeavor. Strategic Healthcare Programs (SHP) is a seven-year-old company that focuses exclusively upon measuring and reporting outcomes for the pharmaceutical and health care Industry.
Barbara Rosenblum, President and CEO, founded SHP in 1996 to address the healthcare industry’s need to track and measure the outcomes delivered by new treatments and protocols. SHP has worked with the largest pharmaceutical companies in the world as well as leading managed care plans where it designed and tracked care pathways and protocols. Much of SHP tracking and reporting is web enabled allowing customers and their providers to easily track the progress of their products and initiatives. SHP will be involved in designing care pathways and tracking outcomes for GenoMed’s unique program of working through physicians to identify, screen and find treatments for disease causing genes.
Ms. Rosenblum stated that, “We are extremely pleased to be chosen as GenoMed’s partner in measuring outcomes for its ground breaking research and commercialization of genomics. Based upon the success of GenoMed’s current treatment regimen, we are excited to be involved in designing treatment protocols and tracking improvement in patients’ health. GenoMed has taken health care improvement to the next level, and we at SHP are excited to have become part of their innovations and programs that will greatly contribute to the quality of life for their patients. GenoMed is a perfect partner for SHP in that we entered the outcomes business to be part of innovative programs that can significantly improve the health care quality of patients. GenoMed is a leader in this area.”
Dr. David Moskowitz, GenoMed’s Chairman and Chief Medical Officer, said, “We’re delighted to have Strategic Healthcare Programs as a partner. SHP’s experience in designing protocols and tracking health outcomes will lead to identification of new treatments and potentially contribute to the revenue GenoMed realizes for its proprietary science. SHP will work closely with GenoMed licensed physicians to capture data that will be utilized to improve the health outcomes of patients. This collaboration is significant because it verifies the positive financial impact our treatments have upon the health care dollar. More importantly, we will be able to continually demonstrate GenoMed’s potential to dramatically improve patients’ quality of life. SHP’s expertise and technology will play a valuable part in this mission.”
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article
Business Journal Story
reported that the company has applied for patents based on its finding that the ACE gene is associated with nearly 40 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use.
A video version of the company’s treatment results for chronic kidney failure is available at:
Video News Release
Consistent with the Company’s goal to improve patient outcomes globally, GenoMed is currently working to license its treatments to physicians and healthcare systems worldwide. GenoMed recently held a press conference at La Clinica Health Center (3646 Fairview Ave., St. Louis, MO; tel. 314-664-5565) in, May 2002 to discuss licensing the same treatment to La Clinica for its Hispanic population, who have a 50% prevalence rate of diabetes. The press conference was held jointly with Lieutenant Governor Joe Maxwell, who encouraged senior citizens to sign up for the Missouri Senior Rx Program, and urged improvement in minority health outcomes. GenoMed also recently announced agreements with large physician organizations located in the Midwestern and Southwestern United States as part of its strategy to work directly with physicians to deliver its unique treatment to patients.
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX 314-977-0042,email: kfischer@genomedics.com or visit GenoMed at www.genomedics.com. |
